Oligodendroglioma - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Oligodendroglioma - Pipeline Review, H1 2016', provides an overview of the Oligodendroglioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Oligodendroglioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Oligodendroglioma - The report reviews pipeline therapeutics for Oligodendroglioma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Oligodendroglioma therapeutics and enlists all their major and minor projects - The report assesses Oligodendroglioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Oligodendroglioma Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Oligodendroglioma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Oligodendroglioma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Oligodendroglioma Overview 8 Therapeutics Development 9 Pipeline Products for Oligodendroglioma - Overview 9 Pipeline Products for Oligodendroglioma - Comparative Analysis 10 Oligodendroglioma - Therapeutics under Development by Companies 11 Oligodendroglioma - Therapeutics under Investigation by Universities/Institutes 12 Oligodendroglioma - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Oligodendroglioma - Products under Development by Companies 15 Oligodendroglioma - Products under Investigation by Universities/Institutes 16 Oligodendroglioma - Companies Involved in Therapeutics Development 17 Axelar AB 17 Boehringer Ingelheim GmbH 18 Bristol-Myers Squibb Company 19 Cavion LLC 20 Celgene Corporation 21 Celldex Therapeutics, Inc. 22 e-Therapeutics Plc 23 F. Hoffmann-La Roche Ltd. 24 Millennium Pharmaceuticals, Inc. 25 Novartis AG 26 Pfizer Inc. 27 Tocagen Inc. 28 Oligodendroglioma - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Combination Products 30 Assessment by Target 31 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 afatinib dimaleate - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 alisertib - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 AXL-1717 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 bevacizumab - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 CC-122 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 CDX-1401 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Cellular Immunotherapy for Brain Tumors - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Cellular Immunotherapy for Gliomas - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Cellular Immunotherapy for Oncology - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 dasatinib - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 DNX-2401 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 ETS-2101 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 flucytosine + TBio-01 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 flucytosine ER + vocimagene amiretrorepvec - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 irinotecan hydrochloride + TBio-02 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 mibefradil dihydrochloride - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 nilotinib - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 p28 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 palbociclib - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 temsirolimus - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Oligodendroglioma - Recent Pipeline Updates 95 Oligodendroglioma - Dormant Projects 130 Appendix 131 Methodology 131 Coverage 131 Secondary Research 131 Primary Research 131 Expert Panel Validation 131 Contact Us 131 Disclaimer 132
List of Tables
Number of Products under Development for Oligodendroglioma, H1 2016 9 Number of Products under Development for Oligodendroglioma - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Oligodendroglioma - Pipeline by Axelar AB, H1 2016 17 Oligodendroglioma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 18 Oligodendroglioma - Pipeline by Bristol-Myers Squibb Company, H1 2016 19 Oligodendroglioma - Pipeline by Cavion LLC, H1 2016 20 Oligodendroglioma - Pipeline by Celgene Corporation, H1 2016 21 Oligodendroglioma - Pipeline by Celldex Therapeutics, Inc., H1 2016 22 Oligodendroglioma - Pipeline by e-Therapeutics Plc, H1 2016 23 Oligodendroglioma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 24 Oligodendroglioma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 25 Oligodendroglioma - Pipeline by Novartis AG, H1 2016 26 Oligodendroglioma - Pipeline by Pfizer Inc., H1 2016 27 Oligodendroglioma - Pipeline by Tocagen Inc., H1 2016 28 Assessment by Monotherapy Products, H1 2016 29 Assessment by Combination Products, H1 2016 30 Number of Products by Stage and Target, H1 2016 32 Number of Products by Stage and Mechanism of Action, H1 2016 34 Number of Products by Stage and Route of Administration, H1 2016 36 Number of Products by Stage and Molecule Type, H1 2016 38 Oligodendroglioma Therapeutics - Recent Pipeline Updates, H1 2016 95 Oligodendroglioma - Dormant Projects, H1 2016 130
List of Figures
Number of Products under Development for Oligodendroglioma, H1 2016 9 Number of Products under Development for Oligodendroglioma - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Assessment by Monotherapy Products, H1 2016 29 Assessment by Combination Products, H1 2016 30 Number of Products by Top 10 Targets, H1 2016 31 Number of Products by Stage and Top 10 Targets, H1 2016 31 Number of Products by Top 10 Mechanism of Actions, H1 2016 33 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 33 Number of Products by Routes of Administration, H1 2016 35 Number of Products by Stage and Routes of Administration, H1 2016 35 Number of Products by Molecule Types, H1 2016 37 Number of Products by Stage and Molecule Types, H1 2016 37
Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commercRead More...
Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among otRead More...
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to driRead More...
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.